Eleftha 440mg Injection

Product Description

Eleftha 440mg Injection contains trastuzumab as its active ingredient and is indicated for the treatment of HER2-positive breast cancer. In patients with HER2-positive breast cancer, the cancer cells often have elevated levels of HER2 proteins, which drive rapid tumor growth by signaling the cancerous cells. This medication is also used for treating metastatic gastric cancer with increased HER2 protein levels.

HER2-positive breast cancers tend to be more aggressive. The targeted therapy works by specifically attacking the proteins responsible for the growth, development, and spread of cancer. It is essential to use effective birth control during treatment and for at least 7 months following the final dose.

Eleftha 440mg Injection is not recommended for patients under 18 or those with severe breathing issues requiring oxygen treatment. It is important to inform your doctor if you have any heart problems, experience breathlessness, or have undergone any previous cancer treatments. Additionally, make sure to disclose all medications you are taking, including supplements and herbal products, before starting this treatment.